Carlo Conti

Konsulent

Tätigkeitsgebiete:

Life Sciences & Gesundheitsrecht
Staats- und Verwaltungsrecht
Handels- und Gesellschaftsrecht

Ämter und Funktionen:

Diverse Verwaltungsratsmandate als Präsident oder Mitglied in verschiedenen Unternehmen
Präsident oder Vorstandsmitglied in verschiedenen Organisationen
 

Karriere:

2023	Konsulent Wenger Plattner
2016	Partner Wenger Plattner
2014	Konsulent Wenger Plattner
2000	Regierungsrat des Kantons Basel-Stadt, Vorsteher des Gesundheitsdepartements
1985	F. Hoffmann-La Roche AG, in leitender Funktion Rechtsabteilung und Öffentlichkeitsarbeit
1985	Universität Basel (Dr. iur.)
1982	Rechtsanwalt
1978	Universität Basel (lic. iur.)

 

Ausgewählte Publikationen:

Digital Health Laws and Regulations Switzerland 2024
In: The International Comparative Legal Guides (ICLG), Fifth Edition, London 2024, p. 205-213

Drug & Medical Device Litigation 2023 - Practical cross-border insights into drug and medical device litigation
In: The International Comparative Legal Guides (ICLG), Fourth Edition, London 2023, p. 135-142

GLI - Pricing & Reimbursement 2022
GLI - Pricing & Reimbursement 2022, Fifth Edition, p. 218 - 227

Kommentar zu Art. 16a - 16c HMG
In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

GLI - Pricing & Reimbursement 2021
GLI – Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204

GLI - Pricing & Reimbursement 2020
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.

The Pharma Legal Handbook Switzerland
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms | Pharma Board Room, London 2020

GLI - Pricing & Reimbursement 2019
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.

GLI – Pricing & Reimbursement 2018
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.

Versorgungsmanagement im Spannungsfeld zwischen Daten-, Patientenschutz und sektoralen Versorgungsgrenzen
In: Versorgungsmanagement in Gesundheitssystemen, Rebscher Herbert / Kaufmann Stefan (Hrsg.), Heidelberg 2013, S. 139 ff.